| Trademark Snap Shot Publication Stylesheet (Table presents the data on Publication Approval) |
|||
OVERVIEW |
|||
| SERIAL NUMBER | 79284023 | FILING DATE | 03/10/2020 |
| REG NUMBER | 0000000 | REG DATE | N/A |
| REGISTER | PRINCIPAL | MARK TYPE | TRADEMARK |
| INTL REG # | 1527051 | INTL REG DATE | 03/10/2020 |
| TM ATTORNEY | SCLEIDOROVICH, JOANNA |
L.O. ASSIGNED | O10-NOT FOUND |
PUB INFORMATION |
|||
| RUN DATE | 08/06/2020 | ||
| PUB DATE | 09/08/2020 | ||
| STATUS | 681-PUBLICATION/ISSUE REVIEW COMPLETE | ||
| STATUS DATE | 08/05/2020 | ||
| LITERAL MARK ELEMENT | VIJOICE | ||
| DATE ABANDONED | N/A | DATE CANCELLED | N/A |
| SECTION 2F | NO | SECTION 2F IN PART | NO |
| SECTION 8 | NO | SECTION 8 IN PART | NO |
| SECTION 15 | NO | REPUB 12C | N/A |
| RENEWAL FILED | NO | RENEWAL DATE | N/A |
| DATE AMEND REG | N/A | ||
FILING BASIS |
|||||
| FILED BASIS | CURRENT BASIS | AMENDED BASIS | |||
| 1 (a) | NO | 1 (a) | NO | 1 (a) | NO |
| 1 (b) | NO | 1 (b) | NO | 1 (b) | NO |
| 44D | NO | 44D | NO | 44D | NO |
| 44E | NO | 44E | NO | 44E | NO |
| 66A | YES | 66A | YES | ||
| NO BASIS | NO | NO BASIS | NO | ||
MARK DATA |
|
| STANDARD CHARACTER MARK | NO |
| LITERAL MARK ELEMENT | VIJOICE |
| MARK DRAWING CODE | 3-AN ILLUSTRATION DRAWING WHICH INCLUDES WORD(S)/LETTER(S)/NUMBER(S) |
| COLOR DRAWING FLAG | YES |
CURRENT OWNER INFORMATION |
|
| PARTY TYPE | 10-ORIGINAL APPLICANT |
| NAME | NOVARTIS AG |
| ADDRESS | CH-4002 Basel |
| ENTITY | 25 |
| CITIZENSHIP | Switzerland |
GOODS AND SERVICES |
|
| INTERNATIONAL CLASS | 005 |
| DESCRIPTION TEXT | Anti-infectives; anti-inflammatories; antibacterial pharmaceuticals; antibiotics; antifungal preparations; antivirals; cardiovascular pharmaceuticals; dermatological pharmaceutical preparations; inhaled pharmaceutical preparations for the prevention and treatment of respiratory diseases and disorders; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations and substances for the prevention and treatment of gastrointestinal diseases; pharmaceutical preparations for the prevention and treatment of diseases and disorders of the autoimmune system, the metabolic system, the endocrine system, the musculo-skeletal system and the genitourinary system; pharmaceutical preparations for use in hematology and in tissue and organ transplantation; pharmaceutical preparations for the prevention and treatment of eye diseases and conditions; pharmaceutical preparations for the prevention and treatment of heart rhythm disorders; pharmaceutical preparations for the prevention and treatment of immune system related diseases and disorders; pharmaceutical preparations for the prevention and treatment of kidney diseases; pharmaceutical preparations for the prevention and treatment of diabetes; pharmaceutical preparations for the prevention and treatment of hypertension; pharmaceutical preparations for the prevention and treatment of skin disorders; pharmaceutical preparations for use in dermatology; pharmaceutical preparations for use in urology; pharmaceutical preparations for use in ophthalmology; pharmaceutical preparations for the prevention and treatment of cancer and tumors; pharmaceutical preparations for the prevention and treatment of allergies; pharmaceutical preparations for the prevention and treatment of bone diseases; pharmaceutical preparations for the prevention and treatment of respiratory diseases and asthma |
GOODS AND SERVICES CLASSIFICATION |
|||||||
| INTERNATIONAL CLASS | 005 | FIRST USE DATE | NONE | FIRST USE IN COMMERCE DATE | NONE | CLASS STATUS | 6-ACTIVE |
MISCELLANEOUS INFORMATION/STATEMENTS |
|
| CHANGE IN REGISTRATION | NO |
| COLORS CLAIMED STATEMENT | The colors coral pink and green are claimed as a feature of the mark. |
| DESCRIPTION OF MARK | The mark consists of the word "VIJOICE" in coral pink, with seven green circles forming a line above the wording. |
SECTION 66A INTERNATIONAL REGISTRATION DATA |
|
| INTL REG # | 1527051 |
| INTL REG DATE | 03/10/2020 |
| PRIORITY CLMD | YES |
| PRIOR CLMD DATE | 03/06/2020 |
| INTL STATUS | 001-REQUEST FOR EXTENSION OF PROTECTION PROCESSED |
| INTL STATUS DATE | 04/23/2020 |
| AUTO PROTECTION DATE | 10/23/2021 |
| INTL RENEWAL DATE | 03/10/2030 |
| INTL REG DEATH DATE | N/A |
| FIRST REFUSAL | YES |
PROSECUTION HISTORY |
||||
| DATE | ENT CD | ENT TYPE | DESCRIPTION | ENT NUM |
| 08/05/2020 | CNSA | O | APPROVED FOR PUB - PRINCIPAL REGISTER | 020 |
| 08/04/2020 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | 019 |
| 08/03/2020 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | 018 |
| 08/03/2020 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | 017 |
| 07/29/2020 | CHAN | I | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | 016 |
| 07/29/2020 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED | 015 |
| 07/29/2020 | ECDR | I | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS | 014 |
| 07/29/2020 | ARAA | I | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | 013 |
| 07/29/2020 | REAP | I | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | 012 |
| 07/29/2020 | COAR | I | TEAS CHANGE OF OWNER ADDRESS RECEIVED | 011 |
| 07/18/2020 | RFNT | P | REFUSAL PROCESSED BY IB | 010 |
| 06/27/2020 | RFCS | P | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | 009 |
| 06/27/2020 | RFRR | P | REFUSAL PROCESSED BY MPU | 008 |
| 05/28/2020 | RFCR | E | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | 007 |
| 05/27/2020 | CNRT | R | NON-FINAL ACTION WRITTEN | 006 |
| 05/27/2020 | DOCK | D | ASSIGNED TO EXAMINER | 005 |
| 05/05/2020 | MAFR | O | APPLICATION FILING RECEIPT MAILED | 004 |
| 04/30/2020 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM | 003 |
| 04/29/2020 | LIMI | I | LIMITATION FROM ORIGINAL APPLICATION ENTERED | 002 |
| 04/23/2020 | REPR | M | SN ASSIGNED FOR SECT 66A APPL FROM IB | 001 |
CURRENT CORRESPONDENCE INFORMATION |
|
| ATTORNEY | Maury M. Tepper, III |
| CORRESPONDENCE ADDRESS | Maury M. Tepper, III Tepper & Eyster, PLLC 3724 Benson Drive Raleigh, NC 27609 |
| DOMESTIC REPRESENTATIVE | Novartis Pharmaceuticals Corporation |